Memory Semiconductors Lead Stock Market Rally

In contrast, the Dow Jones Industrial Average fell by 0.36%, showing relative weakness. The market clearly exhibited a stock-specific trend centered on the Nasdaq.

Memory-related stocks drove the market's rise, showing a mixed sentiment within the semiconductor sector.

Memory-related stocks, including Micron Technology (up 4.85%), Seagate (up 4.85%), and SanDisk (up 6.82%), showed particular strength.

In contrast, the financial sector generally declined, and most big tech companies remained stable.

As major memory stocks like Micron and SanDisk show signs of recovering their highs, maintaining a buy perspective based on solid earnings is recommended during price corrections.

NAND prices continue to rise, but the quarterly growth rate is slowing.

The proportion of memory in device manufacturing costs has surged from the previous 10-15% to 35-45%, driven by increased AI demand.

The long-term contract between Micron and Nvidia and the demand for large advance payments are interpreted as a strategy to secure long-term revenue stability rather than limiting short-term profits.

This supply shortage could potentially last until 2028, and it is expected to take about five years for China's CXMT to close the technological gap.

Analysis suggests that DRAM prices have potential for an additional 766% increase, and NAND prices for 471%.

The upward trend in memory prices is expected to continue until at least late 2016 or early 2017.

Institutional investors, on average, invested 57.4% of their portfolios in stocks by August, a level similar to the 2007 housing market crisis.

The current figure is close to a 25-year high, mainly attributed to the passive increase in holdings due to market gains.

This shows active trading in various assets beyond tech stocks, including defense industry ETFs and bonds.

It raised its second-half Brent crude forecast from $83 to $95 and mentioned the possibility of supply disruptions continuing until next spring.

The Middle East situation is unstable due to escalating conflict between the US and Iran and restrictions on major shipping routes like the Strait of Hormuz.

This has led to refinery shutdowns and export restrictions, resulting in a decrease in OECD strategic petroleum reserves and a premium on spot prices.

In the physical crude oil market, backwardation has intensified, signaling a severe short-term supply shortage.

This success surpassed the performance of existing AI services from Claude and Google, even exceeding ChatGPT's mobile download levels.

Buoyed by 'Muse's success, Wall Street raised Meta's target price from $710 to $875, focusing on the AI-driven restructuring of the consumer market.

Meanwhile, questions are also being raised about Meta's strategy for utilizing its data center spare capacity.

Rosenblatt set target prices for data storage companies as high as $2,400 per share, citing the increasing importance of memory hardware for AI models.

This redefines NAND flash not just as a storage medium but as a core AI infrastructure, leading to a high valuation of related companies.

Growth is expected in the Advanced Imaging Solutions (AIS) and Patient Care Monitoring (PCS) divisions, and it is considered to have high valuation attractiveness at 12.6 times compared to an estimated 2027 P/E of 17 times. Analysis also suggests an upside potential of approximately 26% based on an average target price of $83.

UBS analyzed that in an environment of rising global bond yields, Asian emerging market bonds could offer attractive investment opportunities.

The solid performance of Asian tech stocks like SK Hynix and Samsung Electronics can support these emerging market bond investments. Gold is favorable for asset diversification in a weak dollar environment, and the AI boom could stimulate demand for commodities like copper, helping to defend portfolio downside risk.

The bi-weekly dosage group recorded over 90% weight loss maintenance, and the monthly dosage group over 80%. Both oral and subcutaneous injection forms are currently undergoing clinical trials, forming a competitive landscape with Eli Lilly's Zepbound.

Clinical trial results involving 180 obese adults showed that the treatment group achieved 16.2% to 18% weight loss.

Specifically, the drug demonstrated excellent efficacy, with over 90% weight loss maintenance when administered every two weeks, and over 80% when administered monthly.

This is expected to create a new competitive dynamic in the existing obesity treatment market.

Crane NXT has successfully expanded its business from its historical printing operations into security technology and advanced manufacturing, growing its market size from $7 billion to $13 billion. Its main strength is considered to be its technological moat with high entry barriers.